794 related articles for article (PubMed ID: 22209391)
1. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
2. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.
Oudard S; Thiam R; Fournier LS; Medioni J; Lamuraglia M; Scotte F; Fabre E; Kim D; Kpamegan E; Panneerselvam A; Cuenod CA
Eur J Cancer; 2012 Jul; 48(10):1512-8. PubMed ID: 22342553
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
[TBL] [Abstract][Full Text] [Related]
9. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
12. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Calvo E; Ravaud A; Bellmunt J
Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
15. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
18. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
19. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
[TBL] [Abstract][Full Text] [Related]
20. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]